An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement.
SMARCA4
SMARCA4-deficient undifferentiated thoracic tumors
lung cancer
undifferentiated thoracic tumors
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
revised:
10
01
2024
received:
15
11
2023
accepted:
13
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
aheadofprint
Résumé
SMARCA4-deficient undifferentiated thoracic tumors are a rare phenomenon. A 40-year-old male was newly diagnosed with SMARCA4-deficient undifferentiated non-small cell lung cancer. He had a history of heavy smoking and job-related exposure to metal dust and melted nickel. CT imaging showed numerous right-sided pleural masses and soft tissue plaques, but no metastases. CT-guided biopsy of a pleural mass confirmed the diagnosis. He was prescribed six cycles of carboplatin paclitaxel, and follow-up imaging showed largely stable disease. Treatment was changed to nivolumab due to shortness of breath, and he received one cycle of nivolumab without considerable side effects. Unfortunately, during the second cycle of his nivolumab, the patient presented with new weakness. Imaging showed spinal cord metastasis and he underwent a laminectomy; he was subsequently followed up as an outpatient. The objective of this publication was to explore SMARCA4-deficient undifferentiated thoracic tumors, other related SMARCA4-deficient tumors, and their overall pattern of presentation. The genetic aberrations of this case are compared to recent publications that also discuss genetic aberrations commonly occurring with this disease process, with an ultimate goal of hastening detection and adding to the library of treatment results.
Identifiants
pubmed: 38390699
doi: 10.1111/1759-7714.15230
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.
Références
Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol. 2021;38(5):83-89. https://doi.org/10.1053/j.semdp.2021.06.001 Epub 2021 Jun 4. PMID: 34147303.
Roden AC. Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report. Mediastinum. 2021;5:39.
Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017;30(6):797-809. https://doi.org/10.1038/modpathol.2017.11 Epub 2017 Mar 3. PMID: 28256572.
Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017;30(10):1422-1432. https://doi.org/10.1038/modpathol.2017.61 Epub 2017 Jun 23. PMID: 28643792.
Sesboue C, Le Loarer F. SWI/SNF-deficient thoraco-pulmonary neoplasms. Semin Diagn Pathol. 2021;38(3):183-194. https://doi.org/10.1053/j.semdp.2020.12.002 Epub 2021 Jan 12. PMID: 33451916.
Crombé A, Alberti N, Villard N. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol. 2019;29:4730-4741.
Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, et al. Thomas de Montpreville V, Masliah-Planchon J, Lantuejoul S, brevet M, Blay JY, Coindre JM, Tirode F, Le Loarer F. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43(4):455-465. https://doi.org/10.1097/PAS.0000000000001188 PMID: 30451731.
Dagogo-Jack I, Schrock AB, Kem M. Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac Oncol. 2020;15:766-776.
Zhao R, Zou Y, Chen H, Chen Y, Liu Y, He M. Analysis of Clinicopathologic Features of 9 Cases of SMARCA4-deficient Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi. 2022;25(8):575-582. Chinese. https://doi.org/10.3779/j.issn.1009-3419.2022.102.27 PMID: 36002194; PMCID: PMC9411953.
Kawachi H, Kunimasa K, Kukita Y, Nakamura H, Honma K, Kawamura T, et al. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy. 2021;13(10):799-806. https://doi.org/10.2217/imt-2020-0311 Epub 2021 May 25. PMID: 34030451.
Iijima Y, Sakakibara R, Ishizuka M, Honda T, Shirai T, Okamoto T, et al. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy. 2020;12(8):563-569. https://doi.org/10.2217/imt-2019-0142 Epub 2020 May 3. PMID: 32363992.
Lin YT, Li CF, Wu HC, Jan YH, Kuo YH. Case report: heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab. Front Immunol. 2023;14:1131448. https://doi.org/10.3389/fimmu.2023.1131448 PMID: 37051241; PMCID: PMC10083322.
Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, et al. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: a case report. Thorac. Cancer. 2019;10(5):1285-1288. https://doi.org/10.1111/1759-7714.13070 Epub 2019 Apr 10. PMID: 30972962; PMCID: PMC6501032.
Zhao M, Ma T, He X, Ge M. Targeted next-generation sequencing reveals activating CTNNB1 mutations in SMARCA4/BRG1-deficient sinonasal carcinomas: a report of two new cases and a brief review of the literature with an emphasis on histogenesis. Virchows Arch. 2023;482(2):453-460. https://doi.org/10.1007/s00428-022-03449-7 Epub 2022 Nov 18. PMID: 36396744.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, et al. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clin Lung Cancer. 2022;23(5):386-392. https://doi.org/10.1016/j.cllc.2022.03.005 Epub 2022 Apr 29. PMID: 35618627.
Grelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78-94. https://doi.org/10.1038/s41568-022-00535-5 Epub 2022 Dec 05. PMID: 36471053.
Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Mol Cancer Ther. 2021;20(12):2341-2351. https://doi.org/10.1158/1535-7163.MCT-21-0433 Epub 2021 Oct 12. PMID: 34642211; PMCID: PMC8643328.